Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025)

Keros Therapeutics' Other Working Capital Changes history spans 7 years, with the latest figure at -$4.2 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 139.07% year-over-year to -$4.2 million; the TTM value through Dec 2025 reached -$4.0 million, down 139.33%, while the annual FY2025 figure was -$4.0 million, 139.33% down from the prior year.
  • Other Working Capital Changes reached -$4.2 million in Q4 2025 per KROS's latest filing, down from -$770000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $10.7 million in Q4 2024 to a low of -$9.3 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is $434263.2, with a median of -$491000.0 recorded in 2024.
  • Peak YoY movement for Other Working Capital Changes: plummeted 1188.89% in 2022, then soared 656.86% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at $46000.0 in 2021, then plummeted by 3934.78% to -$1.8 million in 2022, then plummeted by 429.76% to -$9.3 million in 2023, then surged by 214.31% to $10.7 million in 2024, then crashed by 139.07% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Other Working Capital Changes are -$4.2 million (Q4 2025), -$770000.0 (Q3 2025), and -$2.4 million (Q2 2025).